Panacea Biotec Board Approves FY26 Audited Results, No Dividend Declared, Appoints New Director
Panacea Biotec reported audited standalone and consolidated financial results for FY26. The company incurred a net loss of ₹2,988 Lakh (standalone) and ₹1,523 Lakh (consolidated) for the year ended March 31, 2026. Consequently, no dividend was declared. Mr. Rajinder Singh Manku was appointed as a non-executive independent director from July 1, 2026.
The appointment of a new director and the approval of audited financial results are significant corporate actions. However, the reported losses and absence of dividend declaration suggest a negative financial outlook, impacting investor sentiment.
The company reported a net loss for the financial year and quarter ended March 31, 2026, and consequently decided to pass over the dividend, indicating a negative financial performance.
Panacea Biotec Limited announced the outcome of its Board Meeting held on May 30, 2026. The Board approved the standalone and consolidated audited financial results for the quarter and financial year ended March 31, 2026.
The company reported a net loss after tax for the quarter ended March 31, 2026, of ₹18 Lakh on a standalone basis, and a net loss of ₹100 Lakh on a consolidated basis. For the full financial year ended March 31, 2026, the company reported a net loss after tax of ₹2,988 Lakh on a standalone basis and ₹1,523 Lakh on a consolidated basis.
Due to losses incurred during the financial year 2025-26, the Board decided to pass over the dividend on both equity and preference shares.
Additionally, Mr. Rajinder Singh Manku was appointed as an additional director in the capacity of non-executive independent director for a term of 5 consecutive years, effective July 01, 2026, subject to shareholder approval. The appointment is based on the recommendation of the Nomination & Remuneration Committee, and Mr. Manku has confirmed his independence as per regulatory requirements.
The financial results were reviewed by the Audit Committee on May 29, 2026, and have been audited by the statutory auditors with an unmodified opinion.
What to do with a filing like this
Panacea Biotec Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Panacea Biotec Limited. Read the original for the full detail.